CA2669827A1 - Compositions comprising a mixture of bioflavonols - Google Patents
Compositions comprising a mixture of bioflavonols Download PDFInfo
- Publication number
- CA2669827A1 CA2669827A1 CA002669827A CA2669827A CA2669827A1 CA 2669827 A1 CA2669827 A1 CA 2669827A1 CA 002669827 A CA002669827 A CA 002669827A CA 2669827 A CA2669827 A CA 2669827A CA 2669827 A1 CA2669827 A1 CA 2669827A1
- Authority
- CA
- Canada
- Prior art keywords
- composition according
- isoquercetin
- rutin
- patient
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The present invention relates to novel compositions containing a mixture of two or three bioflavonols like isoquercetin, quercetin-4'-glycoside, rutin and quercetin, which show differences in their pharmacokinetics. These compositions are useful as food supplements possessing preventive properties against damage to human tissues due to their antioxidant properties. Furthermore, these compositions secure a continuum of the presence of bioflavonols having the same aglycone in human plasma over an extended period of time.
Claims (22)
1. A composition for oral administration comprising isoquercetin or quercetin-4'-glycoside; quercetin; and rutin.
2. A composition according to claim 1, comprising isoquercetin or quercetin-4'-glycoside, quercetin and rutin in a molar ratio of about 1:1.5:3.
3. A composition according to claim 1 or 2, comprising a sufficient amount of isoquercetin and rutin, wherein when administered to a human, the composition maintains a concentration of isoquercetin and rutin in plasma for about 7 to 48 hours sufficient to achieve substantially constant pharmacological and nutraceutical activity of the isoquercetin and rutin.
4. A composition according to any one of claims 1 to 3, in a unit dosage form comprising about 100 to 400 mg of isoquercetin, about 150 to 600 mg of quercetin and about 300 to 1200 mg of rutin.
5. A composition according to any one of claims 1 to 3, in a unit dosage form comprising about 100 mg of isoquercetin, about 150 mg of quercetin and about 300 mg of rutin.
6. A composition according to any one of claims 1 to 5, which is in the form of a food supplement.
7. A composition according to any one of claims 1 to 6, which is for maintaining a concentration of isoquercetin and rutin in plasma for about 7 to hours sufficient to achieve substantially constant pharmacological and nutraceutical activity of the isoquercetin and rutin.
8. A composition according to any one of claims 1 to 6, which is for protecting against oxidative damage to human organs, tissues or cells, in a patient in need thereof.
9. A composition according to any one of claims 1 to 6, which is for treating a disease or dysfunction caused by oxidative damage.
10. A composition according to any one of claims 1 to 6, which is for treating a cardiovascular disease in a patient in need thereof.
11. Use of a composition according to any one of claims 1 to 6 for maintaining a concentration of isoquercetin and rutin in plasma for about 7 to hours sufficient to achieve substantially constant pharmacological and nutraceutical activity of the isoquercetin and rutin.
12. Use of a composition according to any one of claims 1 to 6 for protecting against oxidative damage to human organs, tissues or cells, in a patient in need thereof.
13. Use of a composition according to any one of claims 1 to 6 for treating a disease or dysfunction caused by oxidative damage.
14. Use of a composition according to any one of claims 1 to 6 for treating a cardiovascular disease in a patient in need thereof.
15. Use of a composition according to any one of claims 1 to 6 in the preparation of a medicament for maintaining a concentration of isoquercetin and rutin in plasma for about 7 to 24 hours sufficient to achieve substantially constant pharmacological and nutraceutical activity of the isoquercetin and rutin.
16. Use of a composition according to any one of claims 1 to 6 in the preparation of a medicament for protecting against oxidative damage to human organs, tissues or cells, in a patient in need thereof.
17. Use of a composition according to any one of claims 1 to 6 in the preparation of a medicament for treating a disease or dysfunction caused by oxidative damage.
18. Use of a composition according to any one of claims 1 to 6 in the preparation of a medicament for treating a cardiovascular disease in a patient in need thereof.
19. A commercial package comprising the composition as defined in any one of claims 1 to 6, together with a written matter describing instructions for the use thereof for maintaining a concentration of isoquercetin and rutin in plasma for about 7 to 24 hours sufficient to achieve substantially constant pharmacological and nutraceutical activity of the isoquercetin and rutin.
20. A commercial package comprising the composition as defined in any one of claims 1 to 6, together with a written matter describing instructions for the use thereof for protecting against oxidative damage to human organs, tissues or cells, in a patient in need thereof.
21. A commercial package comprising the composition as defined in any one of claims 1 to 6, together with a written matter describing instructions for the use thereof for treating a disease or dysfunction caused by oxidative damage.
22. A commercial package comprising the composition as defined in any one of claims 1 to 6, together with a written matter describing instructions for the use thereof for treating a cardiovascular disease in a patient in need thereof.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10608098P | 1998-10-29 | 1998-10-29 | |
| US60/106,080 | 1998-10-29 | ||
| EP99105035 | 1999-03-22 | ||
| EP99105035.2 | 1999-03-22 | ||
| US66982799A | 1999-10-16 | 1999-10-16 | |
| CA002348395A CA2348395C (en) | 1998-10-29 | 1999-10-16 | Compositions comprising a mixture of bioflavonols |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002348395A Division CA2348395C (en) | 1998-10-29 | 1999-10-16 | Compositions comprising a mixture of bioflavonols |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2669827A1 true CA2669827A1 (en) | 2000-05-11 |
| CA2669827C CA2669827C (en) | 2011-03-22 |
Family
ID=40983731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2669827A Expired - Fee Related CA2669827C (en) | 1998-10-29 | 1999-10-16 | Compositions comprising a mixture of bioflavonols |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2669827C (en) |
-
1999
- 1999-10-16 CA CA2669827A patent/CA2669827C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2669827C (en) | 2011-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2279735A3 (en) | Compositions comprising crystalline trans-(+/-)-delta-9-tetrahydrocannabinol | |
| IE872550L (en) | Drug compositions stabilized against oxidation | |
| FR2587212A1 (en) | VASCULOPROTECTIVE PHARMACEUTICAL COMPOSITIONS CONTAINING A UBIQUINONE DERIVATIVE AND AT LEAST ONE OTHER COMPOUND HAVING A VASCULOPROTECTIVE ACTIVITY | |
| WO2004108162A3 (en) | Controlled release pharmaceutical composition | |
| KR100738940B1 (en) | Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances | |
| GB2329334A (en) | Cholesterol-lowering agents | |
| SE9901573D0 (en) | New compounds | |
| HU230890B1 (en) | Pharmaceutical combinations comprising a p2t receptor antagonist and melagatran | |
| JP2005531593A5 (en) | ||
| JP2002523456A (en) | Ascorbate-isoquercetin composition | |
| UA42733C2 (en) | Bis-naphthalimide derivatives and pharmaceutically acceptable acid addition salts thereof, pharmaceutical composition containing them showing cytotoxic activity | |
| EP0190851B1 (en) | Improved antiinflammatory composition | |
| IL102344A (en) | Use of vitamin d3, its analogues, derivatives and active metabolites for the manufacture of medicaments for stimulating hair growth in humans and warm blooded animals | |
| WO2000066550A8 (en) | New compounds | |
| CA2669827A1 (en) | Compositions comprising a mixture of bioflavonols | |
| CA2348395A1 (en) | Compositions comprising a mixture of bioflavonols | |
| JP2009505992A (en) | Drunkenness reducing composition comprising hyaluronic acid and activated carbon | |
| HRP20020238A2 (en) | 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use | |
| SK5122003A3 (en) | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer | |
| WO2005020968A3 (en) | Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep | |
| CA2352485A1 (en) | Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia | |
| AU2003247042A1 (en) | Gastrointestinal compositions comprising gaba derivatives | |
| WO2007026897A1 (en) | Oral composition for prevention or treatment of skin blemishes or freckles and food | |
| CN113350370A (en) | Application of polyethylene glycol in preventing and/or treating tumor | |
| CA2321265A1 (en) | Antibacterial compositions with synergistic effect, drugs and remedies for digestive diseases containing the same, process for the production thereof and preparations associated therewith |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20141016 |